Literature DB >> 1872021

Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain.

M Venkatesan1, C Fernandez-Prada, J M Buysse, S B Formal, T L Hale.   

Abstract

The T32-ISTRATI strain, which has been used as an oral attenuated Shigella flexneri 2a vaccine, has lost the invasive phenotype due to a spontaneous deletion in the shigella virulence plasmid. This deletion has eliminated three plasmid loci (ipaBCDA, invA and virG) that are necessary for production of a positive Sereny test by Shigella species. Virulence in the Sereny test was reconstituted in the T32-ISTRATI strain by the conjugal transfer of an intact 140 M Da virulence plasmid from S. flexneri 5. The T32-ISTRATI vaccine is safe when given orally in multiple doses of 50-100 x 10(9) organisms, and both homologous and heterologous protection has been reported in large Romanian and Chinese field trials. Although the protective antigen(s) in this vaccine have not been identified, the potential use of non-invasive plasmid deletion mutants as living shigella vaccines is illustrated by the T32-ISTRATI vaccine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872021     DOI: 10.1016/0264-410x(91)90064-d

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  An update on vaccines against Shigella.

Authors:  Shai Ashkenazi; Dani Cohen
Journal:  Ther Adv Vaccines       Date:  2013-09

3.  Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri.

Authors:  M M Venkatesan; M B Goldberg; D J Rose; E J Grotbeck; V Burland; F R Blattner
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model.

Authors:  Xin Zhang; Shuli Sang; Qing Guan; Haoxia Tao; Yanchun Wang; Chunjie Liu
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

5.  Identification of Shigella species in stool specimens by DNA amplification of different loci of the Shigella virulence plasmid.

Authors:  M Yavzori; D Cohen; R Wasserlauf; R Ambar; G Rechavi; S Ashkenazi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

Review 6.  Shigellosis: Epidemiology in India.

Authors:  Neelam Taneja; Abhishek Mewara
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

7.  Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial.

Authors:  Petra Girardi; Shushan Harutyunyan; Irene Neuhauser; Katharina Glaninger; Orsolya Korda; Gábor Nagy; Eszter Nagy; Valéria Szijártó; Denes Pall; Krisztina Szarka; Gábor Kardos; Tamás Henics; Frank J Malinoski
Journal:  Vaccines (Basel)       Date:  2022-02-21

8.  An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.

Authors:  Jiro Mitobe; Ritam Sinha; Soma Mitra; Dhrubajyoti Nag; Noriko Saito; Ken Shimuta; Nobuo Koizumi; Hemanta Koley
Journal:  PLoS Negl Trop Dis       Date:  2017-07-20

9.  Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC.

Authors:  Shushan Harutyunyan; Irene Neuhauser; Alexandra Mayer; Michael Aichinger; Valéria Szijártó; Gábor Nagy; Eszter Nagy; Petra Girardi; Frank J Malinoski; Tamás Henics
Journal:  Vaccines (Basel)       Date:  2020-11-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.